Last updated: September 13, 2022
Sponsor: APRINOIA Therapeutics
Overall Status: Active - Recruiting
Phase
3
Condition
Memory Loss
Alzheimer's Disease
Memory Problems
Treatment
N/AClinical Study ID
NCT05542953
APN-1607-301
Ages 50-85 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria: Inclusion Criteria for All Subjects:
- Written informed consent must be obtained before any assessment is performed.
- Female subjects must be documented by medical records or physician's note to be eithersurgically sterile (by means of hysterectomy, bilateral oophorectomy, or tuballigation) or post-menopausal for at least 1 year (ie, 12 consecutive months with nomenses without an alternative medical cause) or, if they are of childbearingpotential, must commit to use a barrier contraception method or to abstinence for theduration of the study and must have negative serum and urine pregnancy tests.
- Male subjects and their partners of childbearing potential must commit to the use oftwo methods of contraception, one of which is a barrier method (ie, condom), or toabstinence for the study duration.
- Male subjects must not donate sperm for the study duration.
- Willing and able to participate in all study procedures. Inclusion Criteria for Healthy Subjects:
- Medically healthy with no clinically relevant finding on physical examination,laboratory profiles, VS, or ECG at screening and upon reporting for the [18F]APN-1607Imaging Visit.
- No cognitive impairment based on neuropsychological battery and as judged by theInvestigator.
- No first-degree family history of early-onset AD or other neurological diseaseassociated with dementia (prior to age 65). Inclusion Criteria for Subjects with MCI:
- Written informed consent must be obtained before any assessment is performed.
- Must meet all of the clinical criteria for MCI according to NIA-AA criteria, includinglack of functional impairment sufficient to warrant a diagnosis of dementia. Inclusion Criteria for Subjects with AD:
- Has a diagnosis of AD dementia according to NIA-AA criteria, including significantimpairment of activities of daily living.
- Medications taken for symptomatic treatment of AD must have been stable for 30 daysprior to screening and through completion of the neuropsychological battery.
Exclusion
Exclusion Criteria: Exclusion Criteria for All Subjects:
- Current or prior history (within the last 10 years) of alcohol or drug abuse.
- Known hypersensitivity to [18F]APN-1607 or its excipients.
- Clinically significant active or unstable medical illness or planned surgicalprocedures during the study period. History of cancer (other than nonmelanoma skincancers or stable, local prostate cancer), unless without evidence of active diseasewithin the last 3 years and without ongoing medical or surgical therapy.
- Laboratory tests with clinically significant abnormalities or a history or evidence ofclinically significant unstable medical illness.
- Prior participation in other research protocols or clinical care in the last year inaddition to the radiation exposure expected from participation in this clinical study,such that radiation exposure exceeds local guidelines.
- Pregnant, lactating or breastfeeding.
- Unsuitable veins for repeated venipuncture.
- Implants, or history of claustrophobia in MRI.
Study Design
Total Participants: 230
Study Start date:
February 11, 2022
Estimated Completion Date:
June 30, 2023
Connect with a study center
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei 430000
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.